Last edition
News about Clinical Trials
AstraZeneca's investigational antibody-drug conjugate Sone-Ve demonstrated a significant overall survival benefit in the Phase 3 CLARITY-Gastric01 trial, marking a milestone in the development of targeted therapies for CLDN18.2-positive advanced gastric cancer.
Clinical Trials | 28/07/2026 | By News Bureau
Insilico Medicine to Present ISM6331 Phase 1 Data at ESMO 2026
Insilico Medicine will present phase 1 data for Artificial Intelligence (AI)-designed pan-TEAD inhibitor ISM6331 at ESMO 2026 in mesothelioma and advanced solid tumors.
Clinical Trials | 28/07/2026 | By News Bureau | 232
Bio-Thera Doses First Patient in Phase 1 Trial of CD25-Targeting ADC BAT8013
Bio-Thera Solutions has dosed the first patient in a Phase 1 trial of BAT8013, a novel CD25-targeting antibody-drug conjugate designed to enhance anti-tumour immune responses in patients with advanced solid tumours.
Clinical Trials | 27/07/2026 | By News Bureau | 189
Lilly's Triple Agonist, Retatrutide, Successful in 2 Additional Phase 3 Obesity Trials
Lilly's Triple Agonist, Retatrutide, Successful in 2 Additional Phase 3 Obesity Trials. The company plans to submit a Biologics License Application (BLA) for retatrutide to the US Food and Drug Administration (FDA) in Q1 2027.
Clinical Trials | 25/07/2026 | By News Bureau | 137
Healx Doses First Patient in Phase 1/2 Trial of AI-Discovered Therapy for Relapsed Osteosarcoma
Healx has dosed the first patient in its Phase 1/2 trial of AI-developed investigational therapy HLX-4310, marking a milestone in the development of novel treatments aimed at preventing metastatic recurrence in osteosarcoma and other rare cancers.
Clinical Trials | 24/07/2026 | By News Bureau | 158
Argo Biopharma Doses First Patient in Phase 1 siRNA Trial
Argo Biopharma has dosed the first participant in the phase I trial of BW-41012, its Factor XI-targeting siRNA therapy for preventing thromboembolic diseases.
Clinical Trials | 22/07/2026 | By News Bureau | 207
Gilead and Merck Report Positive Phase 3 Results for Investigational Once-Weekly Oral HIV Therapy
ISLEND-1 and ISLEND-2 trials demonstrate non-inferior efficacy and favourable safety profile, supporting regulatory submissions for what could become the first once-weekly oral HIV treatment.
Clinical Trials | 22/07/2026 | By News Bureau | 121
Atea Pharmaceuticals Initiates First-in-Human Phase 1 Trial of AT-587 for Hepatitis E Treatment
Atea Pharmaceuticals has initiated a first-in-human Phase 1 clinical trial evaluating AT-587, an investigational oral antiviral candidate for hepatitis E virus (HEV) infection. The study will assess the drug's safety and pharmacokinetics, supporting the development of a potential new treatment for chronic HEV, particularly in immunocompromised patients.
Clinical Trials | 17/07/2026 | By News Bureau | 153
Ascletis Selects Oral ASC30-ASC48 Fixed-Dose Combination for Clinical Development in Obesity
Ascletis Pharma has selected its ASC30-ASC48 fixed-dose combination for clinical development as a once-daily oral therapy for obesity. The dual-target GLP-1R/GIPR candidate demonstrated encouraging preclinical efficacy, with an IND submission to the US FDA planned for Q4 2026.
Clinical Trials | 17/07/2026 | By News Bureau | 231
GSK's Jemperli (dostarlimab) achieved durable complete responses in dMMR/MSI-H locally advanced rectal cancer, with potential to avoid chemotherapy, radiation, and surgery in some patients.
Clinical Trials | 14/07/2026 | By News Bureau | 123
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy